+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Microbiome Diagnostics Market Size, Share & Trends Analysis Report By Application, By Product (Reagents & Kits and Instruments), By Sample (Fecal, Saliva, Skin, and Others), By Technology, By End User, By Regional Outlook and Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 358 Pages
  • March 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5949658
Description Jump to:

The Global Microbiome Diagnostics Market size is expected to reach $416.1 million by 2030, rising at a market growth of 17.5% CAGR during the forecast period.

Microbiome diagnostics offer a complementary approach to traditional diagnostic modalities by providing insights into the gut microbiome’s role in metabolic health, facilitating early detection of metabolic disturbances, and stratifying individuals based on their metabolic risk profiles. Thus, the metabolic diseases segment acquired $16,399.8 thousand revenue in 2022. Metabolic diseases pose diagnostic challenges due to their multifactorial nature, heterogeneous presentation, and overlapping symptoms.



Microbiome diagnostics have applications across many healthcare areas beyond traditional fields like gastroenterology. As research progresses, the microbiome’s influence on various aspects of human health becomes increasingly apparent. It enables clinicians to develop personalized interventions, such as targeted probiotics, prebiotics, or dietary modifications, to optimize patient health outcomes.

Additionally, Technological advancements, particularly in next-generation sequencing (NGS) technologies, enable higher precision and resolution in microbiome analysis. Improved sequencing platforms and algorithms allow for detecting rare microbial taxa and subtle changes in microbial community composition, enhancing the diagnostic accuracy of microbiome tests. Hence, ongoing technological advancements in microbiome diagnostics drive the market’s growth.

Further, the COVID-19 pandemic disrupted research activities and clinical trials across various fields, including microbiome diagnostics. Many research projects and clinical studies were delayed, suspended, or canceled due to restrictions on laboratory access, reduced funding, and prioritization of COVID-19 research efforts. Some companies expanded into microbiome diagnostics to capitalize on the growing interest in this field and to meet the demand for novel diagnostic solutions. Thus, the COVID-19 pandemic moderately impacted the market.

However, the interactions between the human host and the microbiome are highly complex and dynamic, influenced by numerous factors such as genetics, diet, lifestyle, environment, and immune function. Understanding the intricate relationships between microbial communities and host physiology, metabolism, and immune responses is challenging. Thus, a limited understanding of microbiome-host interactions hampers the market’s growth.

By Application Analysis

By application, the market is divided into disease diagnostics and research application. In 2022, the disease diagnostics segment registered the largest 52.2% share in the market. It enables a precision medicine approach to disease diagnosis by assessing individual microbial profiles and their associations with specific health conditions.

By Disease Diagnostics Analysis

The disease diagnostics segment is subdivided into gastrointestinal disorders, metabolic diseases, and others. In 2022, the gastrointestinal disorders segment attained a 49% share in the microbiome diagnostics market. Gastrointestinal disorders, including inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), and colorectal cancer, affect millions of people worldwide.

By Product Analysis

Based on product, the market is bifurcated into reagents & kits and instruments. The instruments segment attained a substantial 37.2% revenue share in the market in 2022. Technological advancements have led to the development of sophisticated instruments tailored for microbiome analysis.

By Sample Analysis

Based on sample, the market is categorized into fecal, saliva, skin, and others. In 2022, the fecal segment registered the highest 51.4% revenue share in the market. Fecal samples are a rich source of microbial diversity, containing diverse bacteria, fungi, viruses, and other microorganisms inhabiting the gastrointestinal tract.

By Technology Analysis

On the basis of technology, the market is segmented into 16S rRNA sequencing, shot gun metagenomics, metatranscriptomics, and others. In 2022, the shot gun metagenomics segment attained a 21.4% revenue share in the market.

By End User Analysis

Based on end user, the market is divided into hospitals, academic & research institutes, and biotechnology & pharmaceutical companies. The hospitals segment attained a 49% revenue share in the market in 2022. Hospitals are primary centers for diagnosing and treating various medical conditions, including infectious diseases, chronic illnesses, and complex disorders.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed a 51% revenue share in the market in 2022. There has been increasing recognition of the microbiome’s role in human health and disease among healthcare professionals, researchers, and the general population in North America.

Recent Strategies Deployed in the Market

  • Dec-2023: Genetic Analysis AS collaborated with Comono AS, an IT service and IT consulting firm. Under this collaboration, Genetic Analysis AS would evolve a digital line of work platform for the consumer market for testing of microbiome. Moreover, Genetic Analysis AS would enter into the microbiome consumer testing market to offer distinctive and accessible testing services.
  • Nov-2023: Viome Life Sciences acquired Naring Health, a high-tech health and wellness firm. Through this acquisition, Viome Life Sciences would enable its user’s accurate insight into their biochemical identity.
  • May-2023: Microba Life Sciences collaborated with Mainz Biomed N.V., a Germany-based molecular diagnostic company. Under this collaboration, both companies would accelerate the development of the PancAlert project by using bioinformatic tools and a metagenomic sequencing mechanism to locate microbiome biomarkers for the detection of pancreatic cancer.
  • Mar-2023: Becton, Dickinson, and Company received FDA approval for a Vaginal Panel, an extensive diagnostic test that identifies causes of vaginitis. The BD COR system allows STI testing and critical health of women by strengthening patient management and laboratory operations with the latest molecular diagnostic features.
  • Mar-2023: Microba Life Sciences unveiled MetaXplore, a series of testing products such as MetaXplore GI and MetaXplore GI Plus. With the launch of MetaXplore, Microba would be able to provide healthcare professionals with new technology products for diagnosing gastrointestinal health and analysis of metagenomic-operated gut microbiota.
  • Jul-2022: Viome Life Sciences launched the Full Body Intelligence Test, an advanced comprehensive health and microbiome-based test. With the launch of this product oral and gut microbiome tests would be done at homes. Additionally, the product would also identify the root causes of cancer, aging, and chronic diseases.

List of Key Companies Profiled

  • Illumina, Inc.
  • Becton, Dickinson and Company
  • Genetic Analysis AS
  • Microba Life Sciences Limited
  • BioMe Oxford Ltd 
  • Viome Life Sciences, Inc.
  • GoodGut S.L.U. (HIPRA, S.A.)
  • Sun Genomics
  • Origin Sciences Limited
  • Decode Age

Market Report Segmentation

By Application

  • Disease Diagnostics
  • Gastrointestinal Disorders
  • Metabolic Diseases
  • Others
  • Research Application

By Product

  • Reagents & Kits
  • Instruments

By Sample

  • Fecal
  • Saliva
  • Skin
  • Others

By Technology

  • 16S rRNA Sequencing
  • Shot Gun Metagenomics
  • Metatranscriptomics
  • Others

By End User

  • Hospitals
  • Academic & Research Institutes
  • Biotechnology & Pharmaceutical Companies

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

 

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Microbiome Diagnostics Market, by Application
1.4.2 Global Microbiome Diagnostics Market, by Product
1.4.3 Global Microbiome Diagnostics Market, by Sample
1.4.4 Global Microbiome Diagnostics Market, by Technology
1.4.5 Global Microbiome Diagnostics Market, by End User
1.4.6 Global Microbiome Diagnostics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Opportunities
3.2.3 Market Restraints
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Microbiome Diagnostics Market
Chapter 5. Global Microbiome Diagnostics Market by Application
5.1 Global Disease Diagnostics Market by Region
5.2 Global Microbiome Diagnostics Market by Disease Diagnostics Type
5.2.1 Global Gastrointestinal Disorders Market by Region
5.2.2 Global Metabolic Diseases Market by Region
5.2.3 Global Others Market by Region
5.3 Global Research Application Market by Region
Chapter 6. Global Microbiome Diagnostics Market by Product
6.1 Global Reagents & Kits Market by Region
6.2 Global Instruments Market by Region
Chapter 7. Global Microbiome Diagnostics Market by Sample
7.1 Global Fecal Market by Region
7.2 Global Saliva Market by Region
7.3 Global Skin Market by Region
7.4 Global Others Market by Region
Chapter 8. Global Microbiome Diagnostics Market by Technology
8.1 Global 16S rRNA Sequencing Market by Region
8.2 Global Shot Gun Metagenomics Market by Region
8.3 Global Metatranscriptomics Market by Region
8.4 Global Others Market by Region
Chapter 9. Global Microbiome Diagnostics Market by End User
9.1 Global Hospitals Market by Region
9.2 Global Academic & Research Institutes Market by Region
9.3 Global Biotechnology & Pharmaceutical Companies Market by Region
Chapter 10. Global Microbiome Diagnostics Market by Region
10.1 North America Microbiome Diagnostics Market
10.1.1 North America Microbiome Diagnostics Market by Application
10.1.1.1 North America Disease Diagnostics Market by Region
10.1.1.2 North America Microbiome Diagnostics Market by Disease Diagnostics Type
10.1.1.2.1 North America Gastrointestinal Disorders Market by Country
10.1.1.2.2 North America Metabolic Diseases Market by Country
10.1.1.2.3 North America Others Market by Country
10.1.1.3 North America Research Application Market by Region
10.1.2 North America Microbiome Diagnostics Market by Product
10.1.2.1 North America Reagents & Kits Market by Country
10.1.2.2 North America Instruments Market by Country
10.1.3 North America Microbiome Diagnostics Market by Sample
10.1.3.1 North America Fecal Market by Country
10.1.3.2 North America Saliva Market by Country
10.1.3.3 North America Skin Market by Country
10.1.3.4 North America Others Market by Country
10.1.4 North America Microbiome Diagnostics Market by Technology
10.1.4.1 North America 16S rRNA Sequencing Market by Country
10.1.4.2 North America Shot Gun Metagenomics Market by Country
10.1.4.3 North America Metatranscriptomics Market by Country
10.1.4.4 North America Others Market by Country
10.1.5 North America Microbiome Diagnostics Market by End User
10.1.5.1 North America Hospitals Market by Country
10.1.5.2 North America Academic & Research Institutes Market by Country
10.1.5.3 North America Biotechnology & Pharmaceutical Companies Market by Country
10.1.6 North America Microbiome Diagnostics Market by Country
10.1.6.1 US Microbiome Diagnostics Market
10.1.6.1.1 US Microbiome Diagnostics Market by Application
10.1.6.1.2 US Microbiome Diagnostics Market by Product
10.1.6.1.3 US Microbiome Diagnostics Market by Sample
10.1.6.1.4 US Microbiome Diagnostics Market by Technology
10.1.6.1.5 US Microbiome Diagnostics Market by End User
10.1.6.2 Canada Microbiome Diagnostics Market
10.1.6.2.1 Canada Microbiome Diagnostics Market by Application
10.1.6.2.2 Canada Microbiome Diagnostics Market by Product
10.1.6.2.3 Canada Microbiome Diagnostics Market by Sample
10.1.6.2.4 Canada Microbiome Diagnostics Market by Technology
10.1.6.2.5 Canada Microbiome Diagnostics Market by End User
10.1.6.3 Mexico Microbiome Diagnostics Market
10.1.6.3.1 Mexico Microbiome Diagnostics Market by Application
10.1.6.3.2 Mexico Microbiome Diagnostics Market by Product
10.1.6.3.3 Mexico Microbiome Diagnostics Market by Sample
10.1.6.3.4 Mexico Microbiome Diagnostics Market by Technology
10.1.6.3.5 Mexico Microbiome Diagnostics Market by End User
10.1.6.4 Rest of North America Microbiome Diagnostics Market
10.1.6.4.1 Rest of North America Microbiome Diagnostics Market by Application
10.1.6.4.2 Rest of North America Microbiome Diagnostics Market by Product
10.1.6.4.3 Rest of North America Microbiome Diagnostics Market by Sample
10.1.6.4.4 Rest of North America Microbiome Diagnostics Market by Technology
10.1.6.4.5 Rest of North America Microbiome Diagnostics Market by End User
10.2 Europe Microbiome Diagnostics Market
10.2.1 Europe Microbiome Diagnostics Market by Application
10.2.1.1 Europe Disease Diagnostics Market by Country
10.2.1.2 Europe Microbiome Diagnostics Market by Disease Diagnostics Type
10.2.1.2.1 Europe Gastrointestinal Disorders Market by Country
10.2.1.2.2 Europe Metabolic Diseases Market by Country
10.2.1.2.3 Europe Others Market by Country
10.2.1.3 Europe Research Application Market by Country
10.2.2 Europe Microbiome Diagnostics Market by Product
10.2.2.1 Europe Reagents & Kits Market by Country
10.2.2.2 Europe Instruments Market by Country
10.2.3 Europe Microbiome Diagnostics Market by Sample
10.2.3.1 Europe Fecal Market by Country
10.2.3.2 Europe Saliva Market by Country
10.2.3.3 Europe Skin Market by Country
10.2.3.4 Europe Others Market by Country
10.2.4 Europe Microbiome Diagnostics Market by Technology
10.2.4.1 Europe 16S rRNA Sequencing Market by Country
10.2.4.2 Europe Shot Gun Metagenomics Market by Country
10.2.4.3 Europe Metatranscriptomics Market by Country
10.2.4.4 Europe Others Market by Country
10.2.5 Europe Microbiome Diagnostics Market by End User
10.2.5.1 Europe Hospitals Market by Country
10.2.5.2 Europe Academic & Research Institutes Market by Country
10.2.5.3 Europe Biotechnology & Pharmaceutical Companies Market by Country
10.2.6 Europe Microbiome Diagnostics Market by Country
10.2.6.1 Germany Microbiome Diagnostics Market
10.2.6.1.1 Germany Microbiome Diagnostics Market by Application
10.2.6.1.2 Germany Microbiome Diagnostics Market by Product
10.2.6.1.3 Germany Microbiome Diagnostics Market by Sample
10.2.6.1.4 Germany Microbiome Diagnostics Market by Technology
10.2.6.1.5 Germany Microbiome Diagnostics Market by End User
10.2.6.2 UK Microbiome Diagnostics Market
10.2.6.2.1 UK Microbiome Diagnostics Market by Application
10.2.6.2.2 UK Microbiome Diagnostics Market by Product
10.2.6.2.3 UK Microbiome Diagnostics Market by Sample
10.2.6.2.4 UK Microbiome Diagnostics Market by Technology
10.2.6.2.5 UK Microbiome Diagnostics Market by End User
10.2.6.3 France Microbiome Diagnostics Market
10.2.6.3.1 France Microbiome Diagnostics Market by Application
10.2.6.3.2 France Microbiome Diagnostics Market by Product
10.2.6.3.3 France Microbiome Diagnostics Market by Sample
10.2.6.3.4 France Microbiome Diagnostics Market by Technology
10.2.6.3.5 France Microbiome Diagnostics Market by End User
10.2.6.4 Russia Microbiome Diagnostics Market
10.2.6.4.1 Russia Microbiome Diagnostics Market by Application
10.2.6.4.2 Russia Microbiome Diagnostics Market by Product
10.2.6.4.3 Russia Microbiome Diagnostics Market by Sample
10.2.6.4.4 Russia Microbiome Diagnostics Market by Technology
10.2.6.4.5 Russia Microbiome Diagnostics Market by End User
10.2.6.5 Spain Microbiome Diagnostics Market
10.2.6.5.1 Spain Microbiome Diagnostics Market by Application
10.2.6.5.2 Spain Microbiome Diagnostics Market by Product
10.2.6.5.3 Spain Microbiome Diagnostics Market by Sample
10.2.6.5.4 Spain Microbiome Diagnostics Market by Technology
10.2.6.5.5 Spain Microbiome Diagnostics Market by End User
10.2.6.6 Italy Microbiome Diagnostics Market
10.2.6.6.1 Italy Microbiome Diagnostics Market by Application
10.2.6.6.2 Italy Microbiome Diagnostics Market by Product
10.2.6.6.3 Italy Microbiome Diagnostics Market by Sample
10.2.6.6.4 Italy Microbiome Diagnostics Market by Technology
10.2.6.6.5 Italy Microbiome Diagnostics Market by End User
10.2.6.7 Rest of Europe Microbiome Diagnostics Market
10.2.6.7.1 Rest of Europe Microbiome Diagnostics Market by Application
10.2.6.7.2 Rest of Europe Microbiome Diagnostics Market by Product
10.2.6.7.3 Rest of Europe Microbiome Diagnostics Market by Sample
10.2.6.7.4 Rest of Europe Microbiome Diagnostics Market by Technology
10.2.6.7.5 Rest of Europe Microbiome Diagnostics Market by End User
10.3 Asia Pacific Microbiome Diagnostics Market
10.3.1 Asia Pacific Microbiome Diagnostics Market by Application
10.3.1.1 Asia Pacific Disease Diagnostics Market by Country
10.3.1.2 Asia Pacific Microbiome Diagnostics Market by Disease Diagnostics Type
10.3.1.2.1 Asia Pacific Gastrointestinal Disorders Market by Country
10.3.1.2.2 Asia Pacific Metabolic Diseases Market by Country
10.3.1.2.3 Asia Pacific Others Market by Country
10.3.1.3 Asia Pacific Research Application Market by Country
10.3.2 Asia Pacific Microbiome Diagnostics Market by Product
10.3.2.1 Asia Pacific Reagents & Kits Market by Country
10.3.2.2 Asia Pacific Instruments Market by Country
10.3.3 Asia Pacific Microbiome Diagnostics Market by Sample
10.3.3.1 Asia Pacific Fecal Market by Country
10.3.3.2 Asia Pacific Saliva Market by Country
10.3.3.3 Asia Pacific Skin Market by Country
10.3.3.4 Asia Pacific Others Market by Country
10.3.4 Asia Pacific Microbiome Diagnostics Market by Technology
10.3.4.1 Asia Pacific 16S rRNA Sequencing Market by Country
10.3.4.2 Asia Pacific Shot Gun Metagenomics Market by Country
10.3.4.3 Asia Pacific Metatranscriptomics Market by Country
10.3.4.4 Asia Pacific Others Market by Country
10.3.5 Asia Pacific Microbiome Diagnostics Market by End User
10.3.5.1 Asia Pacific Hospitals Market by Country
10.3.5.2 Asia Pacific Academic & Research Institutes Market by Country
10.3.5.3 Asia Pacific Biotechnology & Pharmaceutical Companies Market by Country
10.3.6 Asia Pacific Microbiome Diagnostics Market by Country
10.3.6.1 China Microbiome Diagnostics Market
10.3.6.1.1 China Microbiome Diagnostics Market by Application
10.3.6.1.2 China Microbiome Diagnostics Market by Product
10.3.6.1.3 China Microbiome Diagnostics Market by Sample
10.3.6.1.4 China Microbiome Diagnostics Market by Technology
10.3.6.1.5 China Microbiome Diagnostics Market by End User
10.3.6.2 Japan Microbiome Diagnostics Market
10.3.6.2.1 Japan Microbiome Diagnostics Market by Application
10.3.6.2.2 Japan Microbiome Diagnostics Market by Product
10.3.6.2.3 Japan Microbiome Diagnostics Market by Sample
10.3.6.2.4 Japan Microbiome Diagnostics Market by Technology
10.3.6.2.5 Japan Microbiome Diagnostics Market by End User
10.3.6.3 India Microbiome Diagnostics Market
10.3.6.3.1 India Microbiome Diagnostics Market by Application
10.3.6.3.2 India Microbiome Diagnostics Market by Product
10.3.6.3.3 India Microbiome Diagnostics Market by Sample
10.3.6.3.4 India Microbiome Diagnostics Market by Technology
10.3.6.3.5 India Microbiome Diagnostics Market by End User
10.3.6.4 South Korea Microbiome Diagnostics Market
10.3.6.4.1 South Korea Microbiome Diagnostics Market by Application
10.3.6.4.2 South Korea Microbiome Diagnostics Market by Product
10.3.6.4.3 South Korea Microbiome Diagnostics Market by Sample
10.3.6.4.4 South Korea Microbiome Diagnostics Market by Technology
10.3.6.4.5 South Korea Microbiome Diagnostics Market by End User
10.3.6.5 Australia Microbiome Diagnostics Market
10.3.6.5.1 Australia Microbiome Diagnostics Market by Application
10.3.6.5.2 Australia Microbiome Diagnostics Market by Product
10.3.6.5.3 Australia Microbiome Diagnostics Market by Sample
10.3.6.5.4 Australia Microbiome Diagnostics Market by Technology
10.3.6.5.5 Australia Microbiome Diagnostics Market by End User
10.3.6.6 Malaysia Microbiome Diagnostics Market
10.3.6.6.1 Malaysia Microbiome Diagnostics Market by Application
10.3.6.6.2 Malaysia Microbiome Diagnostics Market by Product
10.3.6.6.3 Malaysia Microbiome Diagnostics Market by Sample
10.3.6.6.4 Malaysia Microbiome Diagnostics Market by Technology
10.3.6.6.5 Malaysia Microbiome Diagnostics Market by End User
10.3.6.7 Rest of Asia Pacific Microbiome Diagnostics Market
10.3.6.7.1 Rest of Asia Pacific Microbiome Diagnostics Market by Application
10.3.6.7.2 Rest of Asia Pacific Microbiome Diagnostics Market by Product
10.3.6.7.3 Rest of Asia Pacific Microbiome Diagnostics Market by Sample
10.3.6.7.4 Rest of Asia Pacific Microbiome Diagnostics Market by Technology
10.3.6.7.5 Rest of Asia Pacific Microbiome Diagnostics Market by End User
10.4 LAMEA Microbiome Diagnostics Market
10.4.1 LAMEA Microbiome Diagnostics Market by Application
10.4.1.1 LAMEA Disease Diagnostics Market by Country
10.4.1.2 LAMEA Microbiome Diagnostics Market by Disease Diagnostics Type
10.4.1.2.1 LAMEA Gastrointestinal Disorders Market by Country
10.4.1.2.2 LAMEA Metabolic Diseases Market by Country
10.4.1.2.3 LAMEA Others Market by Country
10.4.1.3 LAMEA Research Application Market by Country
10.4.2 LAMEA Microbiome Diagnostics Market by Product
10.4.2.1 LAMEA Reagents & Kits Market by Country
10.4.2.2 LAMEA Instruments Market by Country
10.4.3 LAMEA Microbiome Diagnostics Market by Sample
10.4.3.1 LAMEA Fecal Market by Country
10.4.3.2 LAMEA Saliva Market by Country
10.4.3.3 LAMEA Skin Market by Country
10.4.3.4 LAMEA Others Market by Country
10.4.4 LAMEA Microbiome Diagnostics Market by Technology
10.4.4.1 LAMEA 16S rRNA Sequencing Market by Country
10.4.4.2 LAMEA Shot Gun Metagenomics Market by Country
10.4.4.3 LAMEA Metatranscriptomics Market by Country
10.4.4.4 LAMEA Others Market by Country
10.4.5 LAMEA Microbiome Diagnostics Market by End User
10.4.5.1 LAMEA Hospitals Market by Country
10.4.5.2 LAMEA Academic & Research Institutes Market by Country
10.4.5.3 LAMEA Biotechnology & Pharmaceutical Companies Market by Country
10.4.6 LAMEA Microbiome Diagnostics Market by Country
10.4.6.1 Brazil Microbiome Diagnostics Market
10.4.6.1.1 Brazil Microbiome Diagnostics Market by Application
10.4.6.1.2 Brazil Microbiome Diagnostics Market by Product
10.4.6.1.3 Brazil Microbiome Diagnostics Market by Sample
10.4.6.1.4 Brazil Microbiome Diagnostics Market by Technology
10.4.6.1.5 Brazil Microbiome Diagnostics Market by End User
10.4.6.2 Argentina Microbiome Diagnostics Market
10.4.6.2.1 Argentina Microbiome Diagnostics Market by Application
10.4.6.2.2 Argentina Microbiome Diagnostics Market by Product
10.4.6.2.3 Argentina Microbiome Diagnostics Market by Sample
10.4.6.2.4 Argentina Microbiome Diagnostics Market by Technology
10.4.6.2.5 Argentina Microbiome Diagnostics Market by End User
10.4.6.3 UAE Microbiome Diagnostics Market
10.4.6.3.1 UAE Microbiome Diagnostics Market by Application
10.4.6.3.2 UAE Microbiome Diagnostics Market by Product
10.4.6.3.3 UAE Microbiome Diagnostics Market by Sample
10.4.6.3.4 UAE Microbiome Diagnostics Market by Technology
10.4.6.3.5 UAE Microbiome Diagnostics Market by End User
10.4.6.4 Saudi Arabia Microbiome Diagnostics Market
10.4.6.4.1 Saudi Arabia Microbiome Diagnostics Market by Application
10.4.6.4.2 Saudi Arabia Microbiome Diagnostics Market by Product
10.4.6.4.3 Saudi Arabia Microbiome Diagnostics Market by Sample
10.4.6.4.4 Saudi Arabia Microbiome Diagnostics Market by Technology
10.4.6.4.5 Saudi Arabia Microbiome Diagnostics Market by End User
10.4.6.5 South Africa Microbiome Diagnostics Market
10.4.6.5.1 South Africa Microbiome Diagnostics Market by Application
10.4.6.5.2 South Africa Microbiome Diagnostics Market by Product
10.4.6.5.3 South Africa Microbiome Diagnostics Market by Sample
10.4.6.5.4 South Africa Microbiome Diagnostics Market by Technology
10.4.6.5.5 South Africa Microbiome Diagnostics Market by End User
10.4.6.6 Nigeria Microbiome Diagnostics Market
10.4.6.6.1 Nigeria Microbiome Diagnostics Market by Application
10.4.6.6.2 Nigeria Microbiome Diagnostics Market by Product
10.4.6.6.3 Nigeria Microbiome Diagnostics Market by Sample
10.4.6.6.4 Nigeria Microbiome Diagnostics Market by Technology
10.4.6.6.5 Nigeria Microbiome Diagnostics Market by End User
10.4.6.7 Rest of LAMEA Microbiome Diagnostics Market
10.4.6.7.1 Rest of LAMEA Microbiome Diagnostics Market by Application
10.4.6.7.2 Rest of LAMEA Microbiome Diagnostics Market by Product
10.4.6.7.3 Rest of LAMEA Microbiome Diagnostics Market by Sample
10.4.6.7.4 Rest of LAMEA Microbiome Diagnostics Market by Technology
10.4.6.7.5 Rest of LAMEA Microbiome Diagnostics Market by End User
Chapter 11. Company Profiles
11.1 Illumina, Inc.
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Regional Analysis
11.1.4 Research & Development Expense
11.1.5 Recent strategies and developments:
11.1.5.1 Partnerships, Collaborations, and Agreements:
11.1.6 SWOT Analysis
11.2 Becton, Dickinson, and Company
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Segmental and Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
11.2.5.1 Product Launches and Product Expansions:
11.2.5.2 Trails and Approvals:
11.2.6 SWOT Analysis
11.3 Genetic Analysis AS
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Regional Analysis
11.3.4 Recent strategies and developments:
11.3.4.1 Partnerships, Collaborations, and Agreements:
11.4 Microba Life Sciences Limited
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Regional Analysis
11.4.4 Research & Development Expenses
11.4.5 Recent strategies and developments:
11.4.5.1 Partnerships, Collaborations, and Agreements:
11.4.5.2 Product Launches and Product Expansions:
11.5 BioMe Oxford Ltd
11.5.1 Company Overview
11.5.2 Recent strategies and developments:
11.5.2.1 Partnerships, Collaborations, and Agreements:
11.6 Viome Life Sciences, Inc.
11.6.1 Company Overview
11.6.2 Recent strategies and developments:
11.6.2.1 Product Launches and Product Expansions:
11.6.2.2 Acquisition and Mergers:
11.7 GoodGut S.L.U. (HIPRA, S.A.)
11.7.1 Company Overview
11.8 Sun Genomics
11.8.1 Company Overview
11.9 Origin Sciences Limited
11.9.1 Company Overview
11.10. Decode Age
11.10.1 Company Overview
Chapter 12. Winning imperatives of Microbiome Diagnostics Market

Companies Mentioned

  • Illumina, Inc.
  • Becton, Dickinson and Company
  • Genetic Analysis AS
  • Microba Life Sciences Limited
  • BioMe Oxford Ltd
  • Viome Life Sciences, Inc.
  • GoodGut S.L.U. (HIPRA, S.A.)
  • Sun Genomics
  • Origin Sciences Limited
  • Decode Age

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Forecast to 2028 - Product Image

Global Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Forecast to 2028

  • Report
  • 179 Pages
  • Global
From
Global Human Microbiome Market Report and Forecast 2023-2031 - Product Image

Global Human Microbiome Market Report and Forecast 2023-2031

  • Report
  • 140 Pages
  • Global
From
Human Microbiome Market: Trends, Forecast and Competitive Analysis [2024-2030] - Product Image

Human Microbiome Market: Trends, Forecast and Competitive Analysis [2024-2030]

  • Report
  • 209 Pages
  • Global
From
Global Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT), and Region - Forecast to 2029 - Product Image

Global Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT), and Region - Forecast to 2029

  • Report
  • 183 Pages
  • Global
From
Global Cancer Microbiome Market Report and Forecast 2024-2032 - Product Image

Global Cancer Microbiome Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Global
From

About the Microbiome Diagnostics Market

Within the field of biotechnology, the microbiome diagnostics market encompasses a range of technologies and products aimed at analyzing and understanding the complex communities of microorganisms, particularly bacteria and fungi, that inhabit various environments, including the human body. These diagnostics are crucial for advancing the comprehension of the human microbiome and its impact on health and disease. This market leverages advancements in genomics, proteomics, and bioinformatics to identify microbial compositions in different biological samples. The applications of microbiome diagnostics are broad, ranging from identifying dysbiosis associated with disease states to predicting the response to therapeutics and personalizing treatment plans. Microbiome diagnostics play a pivotal role in preventive medicine, nutrition, and the development of targeted therapies by providing insights into the correlation between microbial flora and patient outcomes. The approach has been especially fruitful in the areas of gastrointestinal and metabolic diseases, where the gut microbiome is known to have a major influence. Additionally, the research in this field is rapidly expanding, with discoveries regularly enhancing the potential of microbiome-based diagnostics and therapeutics. Several companies have established themselves in the microbiome diagnostics market, contributing to its growth and innovation. Notable among these are uBiome (now rebranded as BiomeSense), which specializes in microbial genomics for health, disease, and lifestyle; Second Genome, a company that has developed a platform for microbiome science to influence disease treatment and prevention; and CosmosID, which offers microbial genomics solutions for infectious disease diagnostics and microbiome analysis Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.